Palvella Therapeutics (PVLA) EPS (Weighted Average and Diluted) (2020 - 2026)
Palvella Therapeutics (PVLA) reported EPS (Weighted Average and Diluted) of -$1.2 for Q1 2026, down 62.16% year-over-year from -$3.17 in Q1 2025, and down 11.11% quarter-over-quarter from -$1.08 in Q4 2025.
Palvella Therapeutics (PVLA) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has 7 years of EPS (Weighted Average and Diluted) data on file, last reported at -$1.2 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$1.2, down 62.16% year-over-year; the trailing twelve-month figure through Mar 2026 was -$4.17 (up 40.68% YoY), and the FY2025 annual result was -$3.71, up 52.62% from the prior year.
- EPS (Weighted Average and Diluted) fell to -$1.2 in Q1 2026 per PVLA's latest filing, from -$1.08 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $20.5 in Q4 2023 and troughed at -$8.7 in Q3 2023.
- A 5-year average of $0.18 and a median of -$0.94 in 2025 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2023 and 2025: EPS (Weighted Average and Diluted) jumped 2685.71% in 2023, then sank 1000.0% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.14 in 2022, then soared by 14742.86% to $20.5 in 2023, then plunged by 99.41% to $0.12 in 2024, then slumped by 1000.0% to -$1.08 in 2025, then fell by 11.11% to -$1.2 in 2026.
- Business Quant data shows PVLA's EPS (Weighted Average and Diluted) at -$1.2 in Q1 2026, -$1.08 in Q4 2025, and -$1.03 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Palvella Therapeutics | 1.49 Bn | 1.23 Bn | - | -1.20 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.20 |
| Dec 31, 2025 | -1.08 |
| Sep 30, 2025 | -1.03 |
| Jun 30, 2025 | -0.86 |
| Mar 31, 2025 | -0.74 |
| Dec 31, 2024 | 0.12 |
| Sep 30, 2024 | -3.94 |
| Jun 30, 2024 | -2.47 |
| Mar 31, 2024 | -1.54 |
| Dec 31, 2023 | 20.50 |
| Sep 30, 2023 | -8.70 |
| Jun 30, 2023 | 3.62 |
| Jun 30, 2022 | -0.14 |
| Mar 31, 2022 | -0.07 |
| Dec 31, 2021 | -0.13 |
| Sep 30, 2021 | -0.24 |
| Jun 30, 2021 | -0.25 |
| Mar 31, 2021 | -0.07 |
| Dec 31, 2020 | -0.26 |
| Sep 30, 2020 | -0.26 |